Journals / Cumhuriyet Dental Journal / 2021 / Cilt: 24 - Sayı: 1

INFECTIVE ENDOCARDITIS PROPHYLAXIS IN DENTISTRY: CURRENT PERSPECTIVE

Pages
96–104
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Until the subject is clarified with randomized- controlled studies, dental professionals should periodically visit guidelines for updates on AP.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Infective endocarditis (IE) is a important heart disease with high morbidity and mortality.
📊
Key Findings & Data:The restriction of AP is due to concerns about increased comprehension regarding antibiotic resistance and daily incidence of bacteraemia.
💡
Conclusion & Impact:Until the subject is clarified with randomized- controlled studies, dental professionals should periodically visit guidelines for updates on AP.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Infective endocarditis (IE) is a important heart disease with high morbidity and mortality. Current guidelines suggest antibiotic prohylaxis (AP) to individuals having high risk of IE. These high risk patients include the patients with background of IE, biological or a mechanical prosthetic valve, or a surgically constructed systemic or pulmonary conduit/ shunt. The restriction of AP is due to concerns about increased comprehension regarding antibiotic resistance and daily incidence of bacteraemia. Many researchers have examined the effect of restricting AP on the incidence of IE and found different results. Since these studies are mostly observational, researchers could not establish a causal link between the limitation of AP and the change in the incidence of IE. Until the subject is clarified with randomized- controlled studies, dental professionals should periodically visit guidelines for updates on AP.

Özet

Enfektif endokardit (EE), yüksek morbidite ve mortaliteye sahip önemli bir kalp hastalığıdır. Mevcut kılavuzlar, yüksek EE riski olan bireylere antibiyotik profilaksisini (AP) önermektedir. Bu yüksek riskli hastalar, EE geçmişi, biyolojik veya mekanik prostetik kapak veya cerrahi olarak oluşturulmuş sistemik veya pulmoner kanal/ şant olan hastaları içerir. AP'nin kısıtlanması, antibiyotik direnci ve günlük bakteremi insidansı ile ilgili artan kavrayışla ilgili endişelerden kaynaklanmaktadır. Birçok araştırmacı, AP'yi kısıtlamanın EE insidansı üzerindeki etkisini incelemiş ve farklı sonuçlar bulmuştur. Bu çalışmalar çoğunlukla gözlemsel olduğundan, araştırmacılar AP'nin sınırlandırılması ile EE insidansındaki değişim arasında nedensel bir bağlantı kuramadılar. Konu randomize-kontrollü çalışmalarla netleşene kadar, diş hekimleri AP ile ilgili güncellemeler için periyodik olarak kılavuzları ziyaret etmelidir.

🔖

Cite This Article

Candan, M. (2022). INFECTIVE ENDOCARDITIS PROPHYLAXIS IN DENTISTRY: CURRENT PERSPECTIVE. Cumhuriyet Dental Journal, Cilt: 24 - Sayı: 1, 96–104. https://ajindex.com/articles/476864

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Hoen B, Duval X, Durack DT. Prevention of Infective endocarditis, In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Disease, 9th Edition. Philadelphia: Elsevier; 2019:1141-1150
  2. Ramsdale D, Turner-Stokes L, Committee Advisory. Prophylaxis and treatment of infective endocarditis in adults: A concise guide. Clin Med J R Coll Physicians. 2004;4:545-550
  3. Baltimore RS, Gewitz M, Baddour LM, Beerman LB, Jackson MA, Lockhart PB, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation. 2015;132:1487-1515
  4. Jones TD, Baumgartner L, Bellows MT, Breese BB, Kuttner AG, McCarty M, Rammelkamp CH. Committee on Prevention of Rheumatic Fever and Bacterial Endocarditis, American Heart Association. Prevention of rheumatic fever and bacterial endocarditis through control of streptococcal infections. Circulation. 1955;11:317-320
  5. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009;30:2369-2413
  6. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36:3075-3128
  7. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116:1736-1754
  8. Richey R, Wray D, Stokes T. Prophylaxis against infective endocarditis: summary of NICE guidance. BMJ. 2008;336:770-771. 9.